Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab In-Licenses Cervical Cancer ADC from Seagen for $30 Million Upfront

publication date: Sep 27, 2022

Shanghai Zai Lab formed a collaboration with Seattle’s Seagen to develop a novel treatment for cervical cancer in China. Tivdak® (tisotumab vedotin-tftv) is the only ADC approved in the US for metastatic/recurrent cervical cancer with disease progression. Zai Lab will make a $30 million upfront payment and be responsible for unspecified milestones and royalties. The drug was co-developed by Seagen and Copenhagen’s Genmab, which are conducting a confirmatory Phase III trial. The two companies will split all China revenues 50/50. More details....

Stock Symbols: (NSDQ: ZLAB; HKEX: 9688) (NSDQ: SGEN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital